PExA AB (Spotlight: PEXA) announces that the company has filed a patent application covering protein patterns for the early detection of lung cancer, based on its proprietary non-invasive airway sampling...
Read morePExA today announces that the company will participate as an exhibitor at the World Conference on Lung Cancer (WCLC) in Barcelona, September 6–9, 2025. For PExA, participating at WCLC...
Read morePExA AB is pleased to announce that The Prince Charles Hospital Foundation (TPCHF) in Brisbane, Australia, has signed a 12-month rental agreement for the PExA 2.1 research instrument. The...
Read moreA research team at Danderyd Hospital, led by Associate Professor Charlotte Thålin of Karolinska Institute, has initiated a pilot study using PExA’s non-invasive sampling technology. The aim is to...
Read morePExA AB, a Swedish life science company pioneering non-invasive lung research, has filed a patent application for a novel method that enables RNA fragmentomics analysis in exhaled air samples—a...
Read more
